A Study of PHN-010 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Lung Cancer|Colon Cancer|Endometrial Cancer|Ovarian Cancer|Cervical Cancer|Advanced Solid Tumor|Advanced Cancer
DRUG: PHN-010
Incidence of dose limiting toxicities (Phase 1a), 18 months|Type, incidence and severity of adverse events (AEs) and serious adverse events (SAEs) (Phase 1a), 18 months|Frequency of dose interruptions, reductions, and discontinuations (Phase 1a and 1b), 18 months|Overall response rate (ORR) (Phase 1b), 36 months
Best overall response (BOR) (Phase 1a and 1b), 36 months|Disease control rate (DCR) (Phase 1a and 1b), 36 months|Progression free survival (PFS) (Phase 1a and 1b), 36 months|Time to response (TTR) (Phase 1a and 1b), 36 months|Overall survival (OS) (Phase 1a and 1b), 36 months|Cancer antigen 125 (CA-125) response (Phase 1a and 1b), 36 months|Time to CA-125 response (Phase 1a and 1b), 36 months|Pharmacokinetics, maximum concentration (Cmax) of total ADC (Phase 1a and 1b), 36 months|Pharmacokinetics, Cmax of total antibody (Phase 1a and 1b), 36 months|Pharmacokinetics, Cmax of free payload (Phase 1a and 1b), 36 months|Pharmacokinetics, time of Cmax (Tmax) of total ADC (Phase 1a and 1b), 36 months|Pharmacokinetics, Tmax of total antibody (Phase 1a and 1b), 36 months|Pharmacokinetics, Tmax of free payload (Phase 1a and 1b), 36 months|Pharmacokinetics, area under the curve (AUC) of total ADC (Phase 1a and 1b), 36 months|Pharmacokinetics, AUC of total antibody (Phase 1a and 1b), 36 months|Pharmacokinetics, AUC of total free payload (Phase 1a and 1b), 36 months|Pharmacokinetics, terminal half-life (t1/2) of total ADC (Phase 1a and 1b), 36 months|Pharmacokinetics, t1/2 of total antibody (Phase 1a and 1b), 36 months|Pharmacokinetics, t1/2 of free payload (Phase 1a and 1b), 36 months|Concentration of anti-drug antibodies (Phase 1a and 1b), 36 months|Type, incidence and severity of AEs and SAEs (Phase 1b), 18 months
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.